HU199867B - Process for production of 5-substituated pirimidin nucleosides - Google Patents

Process for production of 5-substituated pirimidin nucleosides Download PDF

Info

Publication number
HU199867B
HU199867B HU875642A HU564287A HU199867B HU 199867 B HU199867 B HU 199867B HU 875642 A HU875642 A HU 875642A HU 564287 A HU564287 A HU 564287A HU 199867 B HU199867 B HU 199867B
Authority
HU
Hungary
Prior art keywords
hydrogen
mmol
compound
formula
deoxy
Prior art date
Application number
HU875642A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT46336A (en
Inventor
Saad G Rahim
Dorothy J Purifoy
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to HU903829A priority Critical patent/HU207735B/hu
Publication of HUT46336A publication Critical patent/HUT46336A/hu
Publication of HU199867B publication Critical patent/HU199867B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
HU875642A 1986-12-15 1987-12-14 Process for production of 5-substituated pirimidin nucleosides HU199867B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU903829A HU207735B (en) 1986-12-15 1987-12-14 Process for producing 1-/beta-d-arabino-furanozyl/-5-propionyl-uracyl derivatives and pharmaceutical compositions containing them as active components

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (2)

Publication Number Publication Date
HUT46336A HUT46336A (en) 1988-10-28
HU199867B true HU199867B (en) 1990-03-28

Family

ID=10609013

Family Applications (4)

Application Number Title Priority Date Filing Date
HU875642A HU199867B (en) 1986-12-15 1987-12-14 Process for production of 5-substituated pirimidin nucleosides
HU903829A HU207735B (en) 1986-12-15 1987-12-14 Process for producing 1-/beta-d-arabino-furanozyl/-5-propionyl-uracyl derivatives and pharmaceutical compositions containing them as active components
HU893368A HU200932B (en) 1986-12-15 1987-12-14 Process for producing pharmaceutical compositions containing 1-(beta-d-arabino-furanozyl)-5-propinyl-uracil as active component
HU893367A HU202112B (en) 1986-12-15 1987-12-14 Process for producing medical compositions comprising substituted pyrimidine nucleotide as active ingredient

Family Applications After (3)

Application Number Title Priority Date Filing Date
HU903829A HU207735B (en) 1986-12-15 1987-12-14 Process for producing 1-/beta-d-arabino-furanozyl/-5-propionyl-uracyl derivatives and pharmaceutical compositions containing them as active components
HU893368A HU200932B (en) 1986-12-15 1987-12-14 Process for producing pharmaceutical compositions containing 1-(beta-d-arabino-furanozyl)-5-propinyl-uracil as active component
HU893367A HU202112B (en) 1986-12-15 1987-12-14 Process for producing medical compositions comprising substituted pyrimidine nucleotide as active ingredient

Country Status (30)

Country Link
US (1) US5079235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP0272065B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS63165397A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR880007521A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN87108265A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE88713T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU601529B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1319143C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (3) CS275398B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (2) DD264924A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3785651T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK654287A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2054693T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI941523A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8629892D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HU199867B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE930471L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL95141A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2064B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (1) LV5273A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MC (1) MC1882A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203216A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO167576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ222898A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH24104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL158050B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT86356B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2036199C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1731064A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA879382B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851889T2 (de) * 1987-06-24 1995-04-13 Florey Howard Inst Nukleosid-derivate.
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
WO1992001452A1 (en) 1990-07-19 1992-02-06 The Wellcome Foundation Limited Enzyme inactivators
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
EP1256589A3 (en) * 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
EP0643718A4 (en) * 1992-05-26 1998-08-05 Alberta Res Council MODIFIED LEWIS ™ C AND LacNAc COMPOUNDS WITH TOLERANCE AND IMMUNOSUPPRESSANT EFFECT.
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
KR0177372B1 (ko) * 1994-12-13 1999-04-01 아키라 마츠다 3'-치환 뉴클레오시드 유도체
US6136791A (en) * 1995-12-22 2000-10-24 East Carolina University Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7211570B2 (en) * 2001-12-20 2007-05-01 Pharmasset, Inc. Treatment of EBV and KHSV infection
MX2007006646A (es) 2004-12-03 2007-11-16 Adherex Technologies Inc Metodos para administrar inhibidores de dihidropirimidina deshidrogenasa en combinacion con 5-fluorouracilo y profarmacos de 5-fluorouracilo.
ES2633786T3 (es) 2008-04-01 2017-09-25 Biosearch Technologies, Inc. Sondas de fluoróforo atenuadoras oscuras de ácido nucleico estabilizado
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
MX2012004383A (es) 2009-10-14 2012-08-23 Adherex Technologies Inc Tratamiento de neurotoxicidad asociada con las combinaciones de 5-florouracilo (5-fu) o sus profarmacos e inhibidores de dihidropiridimina (dpd).
CN106460058B (zh) * 2014-03-30 2019-07-09 赛沛 经修饰的胞嘧啶多核苷酸寡聚物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
SU1731064A3 (ru) 1992-04-30
PL277927A1 (en) 1989-08-21
EP0272065A2 (en) 1988-06-22
US5079235A (en) 1992-01-07
AU8252187A (en) 1988-06-16
NO875209D0 (no) 1987-12-14
CS767588A3 (en) 1991-02-12
JPH03141292A (ja) 1991-06-17
PH24870A (en) 1990-12-26
AU626041B2 (en) 1992-07-23
FI875487A0 (fi) 1987-12-14
HU200932B (en) 1990-09-28
CS275398B2 (en) 1992-02-19
CS916187A2 (en) 1991-02-12
LV5273A3 (lv) 1993-10-10
IL84810A0 (en) 1988-06-30
AU601529B2 (en) 1990-09-13
EP0486477A3 (en) 1992-06-17
FI941523L (fi) 1994-03-31
DK654287A (da) 1988-06-16
CS275402B6 (en) 1992-02-19
RU2036199C1 (ru) 1995-05-27
DE3785651D1 (de) 1993-06-03
PT86356B (pt) 1990-11-07
DD274766A5 (de) 1990-01-03
DE3785651T2 (de) 1993-11-11
HU207735B (en) 1993-05-28
ES2054693T3 (es) 1994-08-16
HU903829D0 (en) 1990-11-28
EP0486477A2 (en) 1992-05-20
DK169991A (da) 1991-10-04
ATE88713T1 (de) 1993-05-15
NZ222898A (en) 1990-12-21
LT2064B (lt) 1993-06-15
GB8629892D0 (en) 1987-01-28
JPH0378370B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-12-13
NO167576B (no) 1991-08-12
IL95141A0 (en) 1991-06-10
EP0272065B1 (en) 1993-04-28
PL160322B1 (pl) 1993-02-26
FI875487A7 (fi) 1988-06-16
PL269462A1 (en) 1989-06-26
JPS63165397A (ja) 1988-07-08
PL160321B1 (pl) 1993-02-26
MX9203216A (es) 1992-07-01
IL84810A (en) 1992-05-25
HU202112B (en) 1991-02-28
DK654287D0 (da) 1987-12-14
PH24104A (en) 1990-03-05
HUT46336A (en) 1988-10-28
EP0272065A3 (en) 1988-11-17
MC1882A1 (fr) 1989-01-24
FI941523A7 (fi) 1994-03-31
KR880007521A (ko) 1988-08-27
IE930470L (en) 1988-06-15
CS342591A3 (en) 1992-04-15
DK169991D0 (da) 1991-10-04
ZA879382B (en) 1989-08-30
CN87108265A (zh) 1988-07-13
PL158050B1 (pl) 1992-07-31
CN1080292A (zh) 1994-01-05
PT86356A (en) 1988-01-01
EP0417560A1 (en) 1991-03-20
NO167576C (no) 1991-11-20
IL95141A (en) 1992-05-25
DK168323B1 (da) 1994-03-14
FI941523A0 (fi) 1994-03-31
NO875209L (no) 1988-06-16
DD264924A5 (de) 1989-02-15
IE930471L (en) 1988-06-15
AU5989090A (en) 1990-11-08
CA1319143C (en) 1993-06-15
PL277926A1 (en) 1989-08-21

Similar Documents

Publication Publication Date Title
HU199867B (en) Process for production of 5-substituated pirimidin nucleosides
US5668113A (en) Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral infections
Martin et al. Synthesis and antiviral activity of monofluoro and difluoro analogs of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1)
JP3225045B2 (ja) 治療用化合物
JP2502813B2 (ja) 抗ビ−ルス ピリミジンヌクレオシド
AU656122B2 (en) Further antiviral pyrimidine nucleosides
HU199870B (en) Process for producing purine arabinoside derivatives with antiviral effect and pharmaceutical compositions comprising same
KR20030061792A (ko) 뉴클레오시드 유도체
JP2002503212A (ja) 単環式ヌクレオシド、その類似体および使用
JPH08504753A (ja) 坑ウイルス性ビリミジンヌクレオシド
US4863906A (en) 2'-deoxy-5-ethynyluridine-3',5'-diestens for treatment of VZV and CMV infections
CA1336430C (en) Therapeutic nucleosides
EP1204415B1 (en) 5-(e)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
JPH0232094A (ja) 抗感染性ヌクレオシド
US5028596A (en) 1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
RU2112765C1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АКТИВНОСТЬ ПРОТИВ ВИРУСНОЙ ИНФЕКЦИИ И β D-АРАБИНОФУРАНОЗИЛ-2-АМИНО-6-МЕТОКСИ-9Н-ПУРИНЫ
RU2039752C1 (ru) Способ получения замещенных пуриновых арабинозидов или его фармацевтически приемлемых производных
JPH06172365A (ja) １０−チアイソアロキサジン誘導体およびその用途
US6121248A (en) Anti-viral agent
JPH05331184A (ja) 抗ウイルス化合物
JPH1087687A (ja) ５−置換−１−（２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノシル）ウラシル
LT3466B (en) Pyrimidine nucleosides, process for their preparation, compositions and intermediates

Legal Events

Date Code Title Description
HU90 Patent valid on 900628
HMM4 Cancellation of final prot. due to non-payment of fee